Terug
39
Ook genoteerd als
CNVVY
OTC
Dagbereik
€ 3,40
€ 3,65
52-Weeksbereik
€ 2,78
€ 3,95
Volume
100
50D / 200D Gem.
€ 3,15
/
€ 3,23
Vorige Slotkoers
€ 3,40
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 37,1 | 0,3 |
| P/B | 4,4 | 2,9 |
| ROE % | 11,2 | 3,7 |
| Net Margin % | 7,2 | 3,8 |
| Rev Growth 5Y % | 5,2 | 10,0 |
| D/E | 1,1 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 0,32
€ 0,30 – € 0,33
|
3,4 B | 1 |
| FY2029 |
€ 0,28
€ 0,27 – € 0,29
|
3,1 B | 1 |
| FY2028 |
€ 0,25
€ 0,24 – € 0,26
|
2,9 B | 1 |
Belangrijkste Punten
Revenue grew 5,17% annually over 5 years — modest growth
ROE of 11,15% — decent returns on equity
Generating 342,45M in free cash flow
P/E of 37,05 — premium valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 3,74%
Cash machine — converts 191,43% of earnings into free cash flow
Groei
Revenue Growth (5Y)
5,17%
Revenue (1Y)8,91%
Earnings (1Y)-6,09%
FCF Growth (3Y)19,90%
Kwaliteit
Return on Equity
11,15%
ROIC9,95%
Net Margin7,18%
Op. Margin16,69%
Veiligheid
Debt / Equity
1,06
Current Ratio1,53
Interest Coverage5,81
Waardering
P/E Ratio
37,05
P/B Ratio4,36
EV/EBITDA19,63
Dividend Yield0,02%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 8,91% | Revenue Growth (3Y) | 7,88% |
| Earnings Growth (1Y) | -6,09% | Earnings Growth (3Y) | 17,17% |
| Revenue Growth (5Y) | 5,17% | Earnings Growth (5Y) | 11,06% |
| Profitability | |||
| Revenue (TTM) | 2,49B | Net Income (TTM) | 178,89M |
| ROE | 11,15% | ROA | 4,72% |
| Gross Margin | 55,19% | Operating Margin | 16,69% |
| Net Margin | 7,18% | Free Cash Flow (TTM) | 342,45M |
| ROIC | 9,95% | FCF Growth (3Y) | 19,90% |
| Safety | |||
| Debt / Equity | 1,06 | Current Ratio | 1,53 |
| Interest Coverage | 5,81 | Dividend Yield | 0,02% |
| Valuation | |||
| P/E Ratio | 37,05 | P/B Ratio | 4,36 |
| P/S Ratio | 2,66 | PEG Ratio | -6,70 |
| EV/EBITDA | 19,63 | Dividend Yield | 0,02% |
| Market Cap | 6,63B | Enterprise Value | 8,17B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2,49B | 2,29B | 2,14B | 2,07B | 2,04B |
| Net Income | 178,89M | 190,50M | 130,30M | 62,90M | 117,60M |
| EPS (Diluted) | 0,09 | 0,09 | 0,06 | 0,03 | 0,06 |
| Gross Profit | 1,38B | 1,28B | 1,20B | 1,12B | 1,12B |
| Operating Income | 416,05M | 324,90M | 262,70M | 207,30M | 203,60M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 3,79B | 3,52B | 3,71B | 3,59B | 3,67B |
| Total Liabilities | 2,27B | 1,83B | 2,02B | 1,98B | 1,98B |
| Shareholders' Equity | 1,52B | 1,69B | 1,69B | 1,61B | 1,69B |
| Total Debt | 1,61B | 1,20B | 1,31B | 1,32B | 1,44B |
| Cash & Equivalents | 75,12M | 64,70M | 97,60M | 143,80M | 463,40M |
| Current Assets | 941,50M | 793,30M | 870,00M | 889,30M | 1,11B |
| Current Liabilities | 616,98M | 512,30M | 536,40M | 533,10M | 569,20M |
Strategiescores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#652 of 1052
Recente Activiteit
Ingestapt
Cash Flow Compounder
Mar 24, 2026